Participated · Convertible Note · Jul 2026

Rege Nephro is developing therapies for kidney disease and is advancing a clinical pipeline in the renal space. The company is preparing for clinical trials and is using interim financing to accelerate R&D and pipeline advancement. Its recent bridge financing is intended to extend cash runway and de-risk near-term development milestones ahead of a larger Series C. Rege Nephro says this capital raise is part of a longer-term strategy to strengthen its position in renal therapies. The company plans to pursue a Series C in autumn 2026 and beyond as it progresses clinical and development activities.

Participated · Equity · Jul 2026

Starlight Engine was established in April 2025 as a group company of Kyoto Fusioneering and is focused on advancing fusion energy through its FAST project. FAST is a privately led, industry–academia initiative that adopts a tokamak configuration and aims to demonstrate fusion power generation in the 2030s by generating and sustaining D–T burning plasma and demonstrating integrated power generation and fuel-cycle systems. The project has completed its conceptual design and is currently moving into engineering design and construction preparations. SLE is coordinating with leading fusion researchers and a wide set of private-sector partners and universities to develop the project and domestic supply chains. The company plans to use newly raised funds to accelerate engineering and technology development, site selection, regulatory processes, supply chain development, and organizational expansion. SLE intends to grow its headcount to about 200 employees over the next two years as it advances toward fusion power demonstration and future commercial plants.

Led · Series B · Jul 2026

Neusignal Therapeutics is developing NTX-083, a novel low-molecule compound intended to treat Alzheimer’s disease via a mechanism distinct from existing therapies. The company completed a physician-initiated single-dose Phase 1 trial at the University of Tokyo Hospital (Feb–Sep 2025) and a company-sponsored multiple-dose Phase 1 trial (Nov 2025–Mar 2026) in healthy adults, with both Japanese trials reporting high safety, strong tolerability, and favorable pharmacokinetics and no significant side effects. Neusignal plans to begin a Phase 1b trial in Alzheimer’s patients in the United States later this year. The company intends to use the Series B proceeds to fund that U.S. trial and to expand its workforce ahead of potential strategic alliances with global pharmaceutical firms. Neusignal originated from Tohoku University and is headquartered in Tokyo.

Participated · Series A · Nov 2025

AstroX is a Japanese private space startup founded in May 2022 that is building a Rockoon system, in which a balloon carries a rocket to high altitude before launch, to provide low-cost, high-frequency and rapid-response small-satellite deployment. Headquartered in Minamisoma, Fukushima Prefecture, the company pursues the vision of restoring “Japan as No. 1” in space development. Demand for small-satellite launches is rising sharply, yet Japan currently depends almost entirely on foreign launchers; AstroX aims to fill this gap domestically. In December 2025 the firm successfully conducted its first launcher experiment, validating separation mechanics for its rocket mount. Proceeds from its Series A financing will be used to accelerate Rockoon R&D and expand engineering talent, with the goal of reaching space by 2026. Total Series A funding now amounts to ¥2.32 billion, providing capital for continued technology development and operational scaling. No revenue or customer metrics were disclosed in the article.

Led · Series A · Nov 2025

ZIRITZ operates StockFormer, an asset-formation platform that applies AI scoring to users’ income, assets, occupation and investment experience to recommend investment properties and structure optimal loans. The service has amassed more than 4,000 registered users, roughly 70 % of whom earn over ¥10 million annually and include executives, doctors, professionals and employees of foreign firms. To broaden its offering, the company introduced StockFormer-ZERO, an automated apartment-planning service that blends financial, real-estate and construction data to manage everything from land selection through design, build and sale. By leveraging big data and AI, StockFormer-ZERO reduces land and building costs by about 20 % and enables investors to pursue newly built apartments or condominiums targeting 7 % yields with minimal personal capital. ZIRITZ collaborates with partner financial institutions and the Saison Group to deliver bridge and end loans, giving lenders a framework to finance projects they previously avoided. The platform currently serves the Tokyo metropolitan area and plans to expand into major cities nationwide while enriching its land and loan data sets and advancing its algorithms. Capital from the latest round will also support recruiting and developing additional talent to sustain these growth initiatives.